BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.82

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$21.67. In 2022 the company made an earnings per share (EPS) of -$25.23 a decrease over its 2021 EPS that were of -$19.81.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.82-9.56%
2022-$25.2327.35%
2021-$19.81-19.96%
2020-$24.7520.81%
2019-$20.4931.52%
2018-$15.58417.57%
2017-$3.01-37.16%
2016-$4.79158.95%
2015-$1.85

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.30-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.35-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA